The 70 kb region harbouring the distal breakpoint contains PRDM12, in addition to a second gene fuse binding protein 3 (FBP3), one of a family of three genes known to positively regulate c-MYC expression. Loss of function of FBP genes arrests cellular proliferation and extinguishes c-MYC expression, 8 therefore it is unlikely that disruption of this gene is responsible for the aggressive disease course seen in this patient. In contrast, abrogation of PRDM12 represents an attractive mechanism to explain this patient's short survival. Although little is known about the function of this particular gene, all known members of the closely related PRDM family map to chromosomal regions that commonly undergo deletions in human cancer.
1 Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. CD38 is a surface marker associated with aggressive disease course and overall shorter survival time in B-cell chronic lymphocytic leukemia (B-CLL). Several groups, including our laboratory, have investigated this marker on CLL B cells and found that greater than 30% CD38 expression within a CLL leukemic population correlates to an overall shorter time to progression and, in general, a poor clinical outcome. [1] [2] [3] [4] [5] However, another study suggests that scoring CLL B-cell CD38 expression using both percent-positive and mean fluorescence intensity (MFI) is a more accurate prognostic tool for B-CLL patients. 6 Recently, Ghia et al 7 found that even a small distinct population of CD38 pos cells, displayed as a small peak in a bimodal CD38-staining profile, was associated with progressive disease. Taken together, these findings provide support for the positive association between CD38 expression and disease progression.
We have considered that the bimodal expression of CD38 means that there are stable subclones within the leukemic CLL B-cell population. Since CD38 expression correlates with progressive disease, it is possible that the CD38 þ leukemic cell population within patients displaying bimodal levels of this marker may be more resistant to therapy. To address this possibility, we decided to follow the CD38 expression profile of leukemic cells from a patient who is currently receiving a total of six cycles of a poly-therapy protocol (PCR) that employs pentostatin (2 mg/M2), cyclophosphamide (600 mg/M2), and rituximab (375 mg/M2) on day 1 with 3-week intervals for a total of six cycles.
Immediately prior to the administration of each treatment, the patient's blood was drawn. The CD38 expression of the leukemic clone was analyzed by gating on only CD19 pos and CD5 pos lymphocytes as previously reported. 3 Peripheral blood mononuclear cells (PBMCs), isolated prior to the first treatment dose, displayed a population that is almost entirely composed of cells that gate into the lymphocyte fraction (Figure 1a) . When examining the CD19 þ /CD5 þ leukemic cells from that population, we found a bimodal profile of CD38 expression where approximately half of the leukemic cells segregated into each of the CD38 neg and CD38 pos fractions (Figure 1b) . Remarkably, this bimodal phenotype persists throughout the course of the treatment regimen despite a clear clinical response (Figure 1c-f) . Interestingly, while the overall blood cell count was consistently dropping during the five cycles of treatment regimen, an increase in the relative percentage of larger nonleukemic cells is seen (compare Figure 1a with g ), as well as CD19 neg lymphocytes (Table 1) . However, the few CD19 pos cells that do remain after each cycle are likely the leukemic clone and not normal B cells, as they are all CD5 pos (Table 1) . Our prediction for this patient during the treatment course was that one of the CLL B-cell populations defined by the presence or absence of CD38, respectively, might be more sensitive to therapy. Indeed, one investigation has suggested that CD38 pos CLL cells are more prone to apoptosis. 8 However, since CD38 expression is associated with a more progressive disease, we would speculate that the CD38 pos cells are more resistant to therapy and therefore would be more likely to survive the treatment regimen. The results presented herein show that, despite an excellent clinical response to the PCR treatment, neither CD38 CLL B-cell subpopulation was more resistant to therapy. These data suggest that the CD38 expression does not convey survival advantages to the leukemic clone, at least as determined by response to treatment. Given the persistence of both subpopulations, it would appear that each subpopulation has the cellular machinery required for chemoresistance to this otherwise effective therapy.
In conclusion, the serial flow cytometric analyses of the blood lymphoctyes in this patient show that both CD38 þ and CD38 À subpopulations are able to persist despite vigorous and effective therapy. If this patient enters a complete remission with normalization of the immune cell populations by flow, it will be of interest to determine whether one or both CD38 populations will return if he does relapse.
BT Pittner Imatinib mesylate is a signal transduction inhibitor that specifically targets a set of protein tyrosine kinases, abl, c-kit, platelet-derived growth factor receptor (PDGF-R). [1] [2] [3] In chronic myeloid leukemia (CML), this drug shows impressive efficacy, with rates of complete hematological response of 95%. 1 Common nonhematological side effects reported in the literature have included nausea, fluid retention with weight gain, muscle cramps and fatigue. 4 A recent publication of Milojkovic et al 5 has reported the dermatological toxicity secondary to Imatinib therapy, with the description of a unique dermatitis related to this drug and a possibility of severe adverse cutaneous reactions. Herein, we describe another possible dermatological side effect that can be precipitated by Imatinib: porphyria cutanea tarda (PCT). A 67-year-old woman was diagnosed at our Institute in 1988 as having CML and was treated with interferon (IFN)-alpha from 1988 to 1993. She achieved complete hematological response, in the absence of cytogenetic remission. In 1993, while undergoing IFN treatment, the patient reported the appearance of spontaneous and painless hemorrhagic blisters on the sunexposed surface of both hands and both feet. Skin biopsy demonstrated lymphohistiocytic infiltrate of the derma. Porphyrin fractions were tested and a high level of uroporphyrin was found in random urine samples (64.8%, normal o20%), leading to the diagnosis of PCT. IFN treatment was discontinued and the patient was treated only with hydroxyurea, with complete resolution of the skin lesions and the return of porphyrin levels to normal. In November 2000, the CML progressed to a blastic crisis, and Imatinib at 600 mg/daily was administered; successful control of leukocytosis was only obtained on increasing the dose to 800 mg/daily, at 14 weeks of therapy. After 108 weeks of continuous Imatinib therapy, the patient noted the appearance of the same painful blisters on her hands, feet and legs. The uroporphyrin level was 64.9% (normal o20%), with total urinary levels of 27.364 mg/24 h (normal 0.50) and liver parameters were normal. Imatinib treatment was discontinued; the skin lesions showed almost complete resolution and laboratory parameters improved.
In PCT, photoactivation of the complement system in the presence of uroporphyrin results in the activation of dermal mast cells, which release their proteases. This results in dermalepidermal separation, reflected clinically as skin fragility and vesicles. The interaction between activated mast cells with fibroblasts, the nature of which is still unclear, may contribute to fibrosis and sclerodermoid skin changes. The stimulatory effect of uroporphyrin on collagen biosynthesis by fibroblasts, which occurs independent of irradiation, may be responsible for the sclerodermoid lesions seen at sun-exposed as well as sunprotected areas. 6 Imatinib should be considered as one of the factors capable of triggering or exacerbating this unusual skin complication, as perhaps should IFN. In fact, in our case, PCT was also precipitated by IFN therapy, an event which has also been reported by others. 7 Regarding the mechanisms underlying this event, interference with enzymatic pathways of uroporphyrin decarboxylation or through inhibition of PDGF-R of dermal cells may be involved, although these mechanisms need to be better defined.
We highlight the importance of considering a diagnosis of PCT in resistant CML patients treated with Imatinib at high dosage, who developed painful skin blisters during treatment. 
